Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
Rhea-AI Summary
Flexion Therapeutics (Nasdaq: FLXN) announced that CEO Michael Clayman, M.D., will participate in an analyst-led fireside chat during the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference. This event is scheduled for December 11, 2020, at 2:15 p.m. ET. Investors can access the live webcast through the Flexion website. The company is dedicated to developing innovative local therapies for musculoskeletal conditions, including osteoarthritis, which is the most prevalent form of arthritis.
Positive
- None.
Negative
- None.
News Market Reaction – FLXN
In the trading session that priced this news, FLXN gained 4.99%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference. The virtual fireside chat is scheduled to begin at 2:15 p.m. ET on Friday, December 11, 2020.
To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.
Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com